Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2023-05-25 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the audio recording of an earnings call for the quarter and year ended March 31, 2023. It references the financial results but does not contain the results themselves, only a link to the recording. The document is short (1381 characters) and serves as an announcement of the earnings call recording, not the transcript or the financial report itself. According to the classification rules, a full transcript of the earnings call would be classified as Call Transcript (CT), but this document is only an announcement with a link to the recording. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure under SEBI regulations.
2023-05-25 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a submission to stock exchanges (BSE and NSE) regarding the Statement of Deviation/Variation pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It confirms that there was no deviation or variation in the use of proceeds raised through a preferential issue of equity warrants for the quarter ended March 31, 2023. The document includes a detailed statement of fund utilization and confirms compliance with regulatory requirements. It is a regulatory compliance filing related to fund usage and does not contain financial statements or detailed financial performance data. It is not an annual or interim report, earnings release, or audit report. It is a regulatory announcement filing to stock exchanges about fund utilization and compliance with SEBI regulations. Therefore, it fits best under Regulatory Filings (RNS). The document length is 4691 characters, which is relatively short and consistent with a regulatory announcement rather than a full report.
2023-05-25 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement dated May 25, 2023, from Strides Pharma Science Limited regarding the grant of stock options under the company's ESOP Plan 2016. It details the number of options granted, exercise price, vesting period, and exercisability terms. There is no financial statement, audit information, or detailed report content. The document is a notification of a share-based compensation event, specifically the granting of stock options to an employee. This fits the category of a share issue or capital change announcement rather than a full report or regulatory filing. Given the content and length, the appropriate classification is 'Share Issue/Capital Change' (SHA).
2023-05-25 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated May 25, 2023, announcing Strides Pharma Science Limited's consolidated financial results for Q4FY23 and FY23 ended March 31, 2023. It includes detailed quarterly and annual financial highlights such as revenues, gross margins, EBITDA, and PAT, along with management commentary on performance and outlook. The document also contains an earnings presentation with charts and tables showing financial data. The presence of comprehensive financial results for a quarter and fiscal year, including actual financial figures and management discussion, indicates this is an Earnings Release. It is not a full Annual Report (10-K) as it focuses on quarterly and annual results but is primarily an earnings announcement. It is not a Regulatory Filing or Report Publication Announcement because it contains substantive financial data and analysis, not just a notification or certification. Therefore, the appropriate classification is Earnings Release (ER). FY 2023
2023-05-25 English
Dividend
Annual Report Classification · 95% confidence The document is a detailed communication from the Board of Directors of Strides Pharma Science Limited dated May 25, 2023, announcing the outcome of a Board Meeting where audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2023, were approved. It includes an Independent Auditor's Report on the consolidated annual financial results, with detailed audit opinions, basis for opinion, management responsibilities, and auditor responsibilities. The document references Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to financial results disclosures. The content includes substantive financial data, audit opinions, and detailed explanations, indicating this is the actual audited financial results report rather than a mere announcement or certification. The length (15,000 characters) and detailed financial and audit content confirm it is a full financial report. Therefore, the document fits the definition of an Annual Report (10-K) type filing, as it covers the full financial performance for the fiscal year ending March 31, 2023, with audit details included. FY 2023
2023-05-25 English
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed communication from Strides Pharma Science Limited to stock exchanges regarding the outcome of a Board Meeting held on May 25, 2023. It announces the approval of audited financial results (both standalone and consolidated) for the quarter and year ended March 31, 2023. The document includes an Independent Auditor's Report with an opinion on the consolidated annual financial results, detailed auditor responsibilities, and management responsibilities. The presence of full audit opinions, detailed financial results, and comprehensive auditor commentary indicates this is the actual audited annual financial report rather than a mere announcement or summary. The document length (15,000 characters) and content confirm it is a full report, not just a notification or certification. Therefore, the document fits the definition of an Annual Report (10-K equivalent) covering the full financial performance for the fiscal year ending March 31, 2023. FY 2023
2023-05-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.